BIIB-015

N/A

Report date: 2024/02/05 13:54:00

Base Information

Drug NameBIIB-015

Drug Alias NameAnti-Cripto-mABAnti-Cripto-DM4Anti-CRIPTOBIIB-015

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > Disulfide bond linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > DM4 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionTubulin polymerisation inhibitorsTeratocarcinoma-derived growth factor 1 stimulants

TargetsTeratocarcinoma-derived growth factor 1Tubulin

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesBiogen Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBiogen Inc

Active IndicationsN/A

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A